Home>>Signaling Pathways>> Endocrinology and Hormones>> Opioid Receptor>>TRV130 (Oliceridine)

TRV130 (Oliceridine)

Catalog No.: GC19397

TRV130 is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein versus β-arrestin signaling pathways coupled to MORs.

TRV130 (Oliceridine) Chemical Structure

Size Price Stock Qty
2mg
$110.00
In stock
5mg
$169.00
In stock
10mg
$268.00
In stock
50mg
$656.00
In stock
100mg
$1,050.00
In stock
200mg
$1,680.00
In stock

Customer Reviews

Based on customer reviews.

Tel: (626) 353-8530 Email: sales@glpbio.com

Sample solution is provided at 25 µL, 10mM.

Product Documents

Quality Control & SDS

View current batch:

Protocol

Kinase experiment:

Equilibrium binding of unlabeled compounds is measured by inhibition of radioligand binding ([3H]-diperenorphine) to HEK cell membranes expressing human MOR, KOR, and DOR. Unlabeled ligand and buffer (50 mM Hepes, 5 mM MgCl2, 1 mM EGTA and 0.05% bovine serum albumin, pH 7.2, at 23°C) containing radioligand are added to polypropylene 96-well plates. Assays are initiated by the addition of membrane (5-10 μg protein/well) suspension. The concentration of [3H]-diprenorphine (specific activity 50-52 Ci/mmol), is 0.5-1 times the independently determined Kd. Compounds are diluted in DMSO and tested at a final concentration of 1% DMSO. Nonspecific binding is defined in the presence of 1 μM naloxone. Competition assays are performed at 23°C for 3-4 hours to allow adequate time for equilibrium binding. In all assays, total radioligand bound to the filter is less than 10% of the total radioligand added. The separation of bound from free radioligand is accomplished by rapid vacuum filtration of the incubation mixture over GF/B filter mats using a Brandel cell harvester. Filters are washed 2 times with 0.5 mL of ice-cold phosphate buffered saline pH 7.0 containing 0.01% Triton ×100. Radioactivity on the filters is quantified using a MicroBeta TriLux Liquid Scintillation Counter.

Animal experiment:

Analgesia-like responses in are measured using a hotplate analgesia meter with dimensions of 29.2 × 26.7 cm with mice restricted to a cylinder 8.9 cm in diameter and 15.2 cm high. Response is measured by recording the latency to lick, flutter, or splay hind paw(s), or an attempt to jump out of the apparatus at 55 °C, with a maximum cut-off time of 30 s. Once a response is observed or the cut-off time had elapsed, the subject is immediately removed from the hotplate and placed back in its home cage. The animals are acclimated to the hotplate, while cool, and a baseline analgesic response time is acquired several hours before drug treatment and testing. Mice are injected with either vehicle (n=8), morphine (5 mg/kg, n=8 or 10 mg/kg, n=8), Oliceridine (1.2 mg/kg, n=9) or PZM21 (10 mg/kg, n=8; 20 mg/kg, n=11; or 40 mg/kg, n=8). After injection of drug, the analgesic effect expressed as percentage maximum possible effect (%MPE) is measured at 15, 30, 60, 90 and 120 min after drug treatment. If animals do not display hind paw lick, splay, or flutter, they are removed from the trial. Additionally, if animals attempt to jump out of the plate or urinated on the hotplate they are removed from the trial. To assess analgesia by the tail-flick assay, a tail-flick analgesia meter. Mice are gently immobilized with a cotton towel and the tail base is placed on a radiant light source emitting a constant temperature of 56 °C. The tail withdrawal latency is measured at similar time points as the hotplate assay after administration of vehicle (n=8), morphine (5 mg/kg, n=4; 10 mg/kg, n=8) or PZM21 (10 mg/kg, n=8; 20 mg/kg; n=14). The cut-off time for the heat source is set at 10 s to avoid tissue damage. Analgesic response times are measured similar to the hotplate assay.

References:

[1]. Altarifi AA, et al. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol. 2017 Jan 1:2698811166
[2]. DeWire SM, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17.
[3]. Manglik A, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016 Sep 8;537(7619):185-190

Background

TRV130 is a novel mu opioid receptor (MOR) agonist that preferentially activates G-protein versus β-arrestin signaling pathways coupled to MORs.

In cell-based assays, TRV130 elicits robust G protein signaling, with potency and efficacy similar to morphine, but with far less β-arrestin recruitment and receptor internalization[2].

TRV130 treatment produces robust antinociception, complete inhibition of gastrointestinal function, and weak abuse-related effects in mice[1]. TRV130 displays an ED50 of 0.9 mg/kg in an analgesic assay. TRV130 analgesia is reversible in mice by administration of 3 mg/kg naloxone s.c. 15 minutes after TRV130 dosing. In the rat 52°C hot plate, TRV130 is 10-fold more potent than morphine with ED50 of 0.32 and 3.2 mg/kg, respectively. TRV130 (0.3 mg/kg, s.c.) possesses an improved therapeutic index of analgesia to constipation relative to morphine in mice[2]. TRV130 (1.2 mg/kg, s.c.) significantly depresses respiration of mice[3].

References:
[1]. Altarifi AA, et al. Effects of acute and repeated treatment with the biased mu opioid receptor agonist TRV130 (oliceridine) on measures of antinociception, gastrointestinal function, and abuse liability in rodents. J Psychopharmacol. 2017 Jan 1:2698811166
[2]. DeWire SM, et al. A G protein-biased ligand at the μ-opioid receptor is potently analgesic with reduced gastrointestinal and respiratory dysfunction compared with morphine. J Pharmacol Exp Ther. 2013 Mar;344(3):708-17.
[3]. Manglik A, et al. Structure-based discovery of opioid analgesics with reduced side effects. Nature. 2016 Sep 8;537(7619):185-190.

Chemical Properties

Cas No. 1401028-24-7 SDF
Synonyms N/A
Chemical Name N/A
Canonical SMILES COC1=C(CNCC[C@@](C2)(C3=NC=CC=C3)CCOC42CCCC4)SC=C1
Formula C22H30N2O2S M.Wt 386.55
Solubility DMSO : ≥ 38 mg/mL (89.83 mM) Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

mg/kg g μL

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO % % Tween 80 % ddH2O
%DMSO %

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.

  • Molarity Calculator

  • Dilution Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
**When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / CoA (available online).

Calculate

Reviews

Review for TRV130 (Oliceridine)

Average Rating: 5 ★★★★★ (Based on Reviews and 9 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for TRV130 (Oliceridine)

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.